Lymphopoiesis

Teaching a Computer Program to Track Cells

Retrieved on: 
Wednesday, May 12, 2021
Branches of biology, Biology, Cell biology, Immune system, Immunology, T cell, Plant cell, Lymphopoiesis, Stem cell

But researchers have a poor understanding of how those cells form patterns in space to eventually give rise to complex three-dimensional organs.\nTraditionally, to study how cells move in space over time, cell biologists tag cells with fluorescent molecules that make them easy to track.

Key Points: 
  • But researchers have a poor understanding of how those cells form patterns in space to eventually give rise to complex three-dimensional organs.\nTraditionally, to study how cells move in space over time, cell biologists tag cells with fluorescent molecules that make them easy to track.
  • Then, they watch those cells under a microscope to see how they divide and migrate.
  • However, a human observer can only follow a small handful of cells at a time before it becomes too challenging to distinguish different cells and track their movements.
  • Humans could only track 90 percent of all cells between frames; a scientist trying to follow cell movements could only figure out where nine of every ten cells moved.

Silverback Therapeutics to Present Preclinical Data on SBT6050 Demonstrating Potent Activation of Human Myeloid Cells and the Potential for Single Agent Clinical Activity

Retrieved on: 
Monday, June 22, 2020
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Medical specialties, Branches of biology, Medicine, Lymphocytes, Immune system, Oncology, Natural killer cell, T cell, Tumor-infiltrating lymphocytes, Cancer treatments, Cancer immunotherapy, Lymphopoiesis

In preclinical studies, SBT6050 activates human myeloid cells in the presence of HER2 expressing tumor cells, resulting in proinflammatory cytokine and chemokine production, inflammasome activation, and the indirect activation of cytolytic activity associated with T and NK cells.

Key Points: 
  • In preclinical studies, SBT6050 activates human myeloid cells in the presence of HER2 expressing tumor cells, resulting in proinflammatory cytokine and chemokine production, inflammasome activation, and the indirect activation of cytolytic activity associated with T and NK cells.
  • Robust, durable single agent activity is observed with the SBT6050 mouse surrogate in multiple tumor models, including those with low tumor infiltrating lymphocytes.
  • In a human xenograft model lacking T, B, and NK cells, the SBT6050 mouse surrogate is curative as a single agent, demonstrating the ability of myeloid cells to mediate strong anti-tumor activity.
  • Our preclinical data highlight SBT6050s potential to maximize anti-tumor immune responses, even in tumors lacking T cells.

Gamida Cell Announces Updated Data from Phase 1 Study of GDA-201 to be Presented at the Annual Meeting of the European Society for Blood and Marrow Transplantation

Retrieved on: 
Monday, March 2, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Medical specialties, Branches of biology, Immune system, Stem cells, Lymphatic system, Hematopoiesis, Lymphocytes, Natural killer cell, Lymphocyte, Bone marrow, Lymphoid leukemia, Lymphopoiesis

GDA-201 addresses key limitations of NK cells by increasing the cytotoxicity and in vivo retention and proliferation in the bone marrow and lymphoid organs of NK cells expanded in culture.

Key Points: 
  • GDA-201 addresses key limitations of NK cells by increasing the cytotoxicity and in vivo retention and proliferation in the bone marrow and lymphoid organs of NK cells expanded in culture.
  • Gamida Cell is an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases.
  • We harness our cell expansion platform to create therapies with the potential to redefine standards of care in areas of serious medical need.
  • For additional information, please visit https://www.gamida-cell.com .